517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819174282780999680 |
|---|---|
| author | Marshall Posner Arjun Balar Matthew Milowsky Andrea Kelly Elizabeth Woodson Brant Inman Raj Pruthi Melissa Polasek Shannon Morris Lori Mixson Kristin Orr Garrett Nichols |
| author_facet | Marshall Posner Arjun Balar Matthew Milowsky Andrea Kelly Elizabeth Woodson Brant Inman Raj Pruthi Melissa Polasek Shannon Morris Lori Mixson Kristin Orr Garrett Nichols |
| author_sort | Marshall Posner |
| collection | DOAJ |
| first_indexed | 2024-12-22T20:36:30Z |
| format | Article |
| id | doaj.art-e57cdb1b68f24dddb6f24579d124981b |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T20:36:30Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-e57cdb1b68f24dddb6f24579d124981b2022-12-21T18:13:27ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.517517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumorsMarshall Posner0Arjun Balar1Matthew Milowsky2Andrea Kelly3Elizabeth Woodson4Brant Inman5Raj Pruthi6Melissa Polasek7Shannon Morris8Lori Mixson9Kristin Orr10Garrett Nichols11Aff155 grid.416167.3Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center New York NY USAAff2 0000 0004 1936 8753grid.137628.9Laura and Isaac Perlmutter Cancer CenterNYU Langone Health New York NY USAUNC-Chapel Hill, Chapel Hill, NC, USADivision of Endocrinology/Diabetes, The Children`s Hospital of Philadelphia, Philadelphia, Pennsylvania, USACancer Center, University of Virginia Health System, Charlottesville, Virginia, USA1Duke University Medical Center, Durham, NC, USA3University of California San Francisco, San Francisco, CA, USA5Istari Oncology, Morrisville, NC, USA5Istari Oncology, Morrisville, NC, USA5Istari Oncology, Morrisville, NC, USA5Istari Oncology, Morrisville, NC, USA5Istari Oncology, Morrisville, NC, USA |
| spellingShingle | Marshall Posner Arjun Balar Matthew Milowsky Andrea Kelly Elizabeth Woodson Brant Inman Raj Pruthi Melissa Polasek Shannon Morris Lori Mixson Kristin Orr Garrett Nichols 517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors Journal for ImmunoTherapy of Cancer |
| title | 517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors |
| title_full | 517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors |
| title_fullStr | 517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors |
| title_full_unstemmed | 517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors |
| title_short | 517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors |
| title_sort | 517 luminos 103 a basket trial evaluating the safety and efficacy of pvsripo and pvsripo in combination with anti pd 1 l1 checkpoint inhibitors in patients with advanced solid tumors |
| work_keys_str_mv | AT marshallposner 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT arjunbalar 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT matthewmilowsky 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT andreakelly 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT elizabethwoodson 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT brantinman 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT rajpruthi 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT melissapolasek 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT shannonmorris 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT lorimixson 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT kristinorr 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors AT garrettnichols 517luminos103abaskettrialevaluatingthesafetyandefficacyofpvsripoandpvsripoincombinationwithantipd1l1checkpointinhibitorsinpatientswithadvancedsolidtumors |